AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14716835 — intervention group
Group type: COMPARATOR
Intervention: Control (unvaccinated healthy volunteers)
Number of subjects: 31
Study 11422095 — intervention group
Group type: EXPERIMENTAL
Intervention: rizatriptan 10 mg
Number of subjects: 4814
Study 11422095 — intervention group
Group type: EXPERIMENTAL
Intervention: rizatriptan 5 mg
Number of subjects: 4814
Study 11422095 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 4814
Study 9130215 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient treatment according to ASAM criteria
Number of subjects: 292
Study 9130215 — intervention group
Group type: COMPARATOR
Intervention: Intensive outpatient treatment according to ASAM criteria
Number of subjects: 292
Study 9130215 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient care for cocaine patients who met ASAM criteria
Number of subjects: 292
Study 9130215 — intervention group
Group type: COMPARATOR
Intervention: Intensive outpatient treatment for alcohol patients who met ASAM criteria
Number of subjects: 292
Study 7955941 — intervention group
Group type: EXPERIMENTAL
Intervention: Athletes
Number of subjects: 66
Study 7955941 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 66
Study 2647603 — intervention group
Group type: EXPERIMENTAL
Intervention: Serrapeptase (Aniflazym)
Number of subjects: 66
Study 2647603 — intervention group
Group type: COMPARATOR
Intervention: Elevation of the leg, bed rest, with and without the application of ice
Number of subjects: 66
Study 31755166 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat and moisture exchanger (HME)
Number of subjects: 13
Study 31755166 — intervention group
Group type: COMPARATOR
Intervention: No heat and moisture exchanger (without HME)
Number of subjects: 13
Study 28739540 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (weight training and aerobic exercise)
Number of subjects: 351
Study 28739540 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-loss
Number of subjects: 351
Study 28739540 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and weight-loss
Number of subjects: 351
Study 28739540 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 351
Study 25495353 — intervention group
Group type: COMPARATOR
Intervention: No device (ND)
Number of subjects: 23
Study 25495353 — intervention group
Group type: EXPERIMENTAL
Intervention: EtCO2 detector (DET)
Number of subjects: 23
Study 25495353 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative EtCO2 detector (CAP)
Number of subjects: 23
Study 23629524 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic repair (LR)
Number of subjects: 157
Study 23629524 — intervention group
Group type: COMPARATOR
Intervention: Open repair (OR)
Number of subjects: 157
Study 21521545 — intervention group
Group type: EXPERIMENTAL
Intervention: LcS-fermented milk administered (n 39)
Number of subjects: 77
Study 21521545 — intervention group
Group type: COMPARATOR
Intervention: Non-administered group (n 38)
Number of subjects: 77
Study 21521545 — intervention group
Group type: EXPERIMENTAL
Intervention: LcS-fermented milk administered (n 10)
Number of subjects: 77
Study 18356827 — intervention group
Group type: EXPERIMENTAL
Intervention: Catechin group (576 mg catechins per day)
Number of subjects: 40
Study 18356827 — intervention group
Group type: COMPARATOR
Intervention: Control group (75 mg catechins per day)
Number of subjects: 40
Study 16485702 — intervention group
Group type: EXPERIMENTAL
Intervention: Large Bore Syringe
Number of subjects: 128
Study 16485702 — intervention group
Group type: COMPARATOR
Intervention: Small Bore Syringe
Number of subjects: 128
Study 16485702 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection over longer times (5, 10, 15, or 20 sec)
Number of subjects: 128
Study 12399900 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy performed on patients with epigastric tenderness
Number of subjects: 132
Study 12399900 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroenterology treatment for patients with positive endoscopy findings
Number of subjects: 132
Study 10720164 — intervention group
Group type: EXPERIMENTAL
Intervention: Rye bread (20% of daily energy)
Number of subjects: 40
Study 10720164 — intervention group
Group type: COMPARATOR
Intervention: Wheat bread (20% of daily energy)
Number of subjects: 40
Study 10720164 — intervention group
Group type: EXPERIMENTAL
Intervention: Rye bread consumption (in tertiles)
Number of subjects: 40
Study 10720164 — intervention group
Group type: EXPERIMENTAL
Intervention: Rye bread and wheat bread
Number of subjects: 40
Study 8604444 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillators (ICDs)
Number of subjects: 0
Study 8604444 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drugs (sotalol or amiodarone)
Number of subjects: 0
Study 1394142 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (6-36 weeks)
Number of subjects: 76
Study 1394142 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 76
Study 1394142 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (3-6 months)
Number of subjects: 76
Study 1394142 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (12-18 months)
Number of subjects: 76
Study 1394142 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (20% of total calories) with tamoxifen
Number of subjects: 76
Study 1394142 — intervention group
Group type: COMPARATOR
Intervention: Control (no tamoxifen)
Number of subjects: 76
Study 4048464 — intervention group
Group type: EXPERIMENTAL
Intervention: Baros
Number of subjects: 100
Study 4048464 — intervention group
Group type: COMPARATOR
Intervention: E‐Z‐Gas II
Number of subjects: 100
Study 30654818 — intervention group
Group type: EXPERIMENTAL
Intervention: Food, Fun, and Families (FFF) intervention
Number of subjects: 119
Study 30654818 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment control
Number of subjects: 119
Study 30067148 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous training in LGB‐TGNC health
Number of subjects: 228
Study 25883078 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigated multi-electrode ablation (IMEA)
Number of subjects: 49
Study 25883078 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency point-by-point ablation (RF-PVI)
Number of subjects: 49
Study 25400470 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic drink containing Lactobacillus casei DN 114001
Number of subjects: 258
Study 25400470 — intervention group
Group type: COMPARATOR
Intervention: Probiotic drink containing Lactobacillus casei Shirota
Number of subjects: 258
Study 23007065 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched-chain amino acid supplementation (BCAA) - 50 g total including 20 g BCAA
Number of subjects: 28
Study 23007065 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 28
Study 23007065 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched-chain amino acid supplementation (BCAA)
Number of subjects: 28
Study 20591139 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (AET) + usual care
Number of subjects: 75
Study 20591139 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) + usual care
Number of subjects: 75
Study 20591139 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone (no therapy or occasional physical therapy)
Number of subjects: 75
Study 18484357 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary nucleoside profiling using mass spectrometry
Number of subjects: 113
Study 18484357 — intervention group
Group type: COMPARATOR
Intervention: Currently applied breast cancer biomarkers (e.g., CA15‐3)
Number of subjects: 113
Study 16100154 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver Nitrate (20 mL 0.5%)
Number of subjects: 60
Study 16100154 — intervention group
Group type: COMPARATOR
Intervention: Talc Slurry (5 g diluted to 50 mL with saline)
Number of subjects: 60
Study 12584835 — intervention group
Group type: EXPERIMENTAL
Intervention: Si' an capsule combined Enalapril
Number of subjects: 60
Study 12584835 — intervention group
Group type: COMPARATOR
Intervention: Enalapril alone
Number of subjects: 60
Study 10359467 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol treatment (40 mg/d)
Number of subjects: 51
Study 10359467 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol treatment (160 mg/d)
Number of subjects: 51
Study 10359467 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 7481854 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of paclitaxel and doxorubicin
Number of subjects: 730
Study 7481854 — intervention group
Group type: COMPARATOR
Intervention: Single-agent paclitaxel
Number of subjects: 730
Study 7481854 — intervention group
Group type: COMPARATOR
Intervention: Single-agent doxorubicin
Number of subjects: 730
Study 7481854 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and paclitaxel
Number of subjects: 730
Study 2030196 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive therapy (CT)
Number of subjects: 63
Study 2030196 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive, self‐directed therapy (S/SD)
Number of subjects: 63
Study 2030196 — intervention group
Group type: COMPARATOR
Intervention: Focused expressive psychotherapy (FEP)
Number of subjects: 63
Study 6281451 — intervention group
Group type: EXPERIMENTAL
Intervention: Burned patients
Number of subjects: 36
Study 31548248 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted serum 25-hydroxyvitamin D (S-25OHD) levels
Number of subjects: 898130
Study 31548248 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted serum calcium (S-Ca) levels
Number of subjects: 898130
Study 31548248 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted serum parathyroid hormone (S-PTH) levels
Number of subjects: 898130
Study 28629905 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing antirheumatic drug therapy
Number of subjects: 0
Study 28629905 — intervention group
Group type: EXPERIMENTAL
Intervention: Withholding antirheumatic drug therapy
Number of subjects: 0
Study 28629905 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal glucocorticoid management
Number of subjects: 0
Study 28629905 — intervention group
Group type: EXPERIMENTAL
Intervention: Restarting antirheumatic medications post-surgery
Number of subjects: 0
Study 25347552 — intervention group
Group type: EXPERIMENTAL
Intervention: High oleic sunflower oil (HOSO)
Number of subjects: 15
Study 25347552 — intervention group
Group type: EXPERIMENTAL
Intervention: Virgin olive oil (VOO)
Number of subjects: 15
Study 25347552 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil (SO)
Number of subjects: 15
Study 24385407 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin (100-300 mg/day)
Number of subjects: 3378
Study 24385407 — intervention group
Group type: COMPARATOR
Intervention: Other antiplatelet drugs
Number of subjects: 3378
Study 21768516 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine-lamivudine-abacavir (ZDV-3TC-ABC)
Number of subjects: 83
Study 21768516 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine-lamivudine-nevirapine (ZDV-3TC-NVP)
Number of subjects: 83
Study 21768516 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV)
Number of subjects: 83
Study 21768516 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir (ABC)
Number of subjects: 83
Study 19387336 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Spaced Education (ISE) on hematuria and priapism (HP)
Number of subjects: 480
Study 19387336 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Spaced Education (ISE) on staghorn calculi, infertility, and antibiotic use (SIA)
Number of subjects: 480
Study 17322151 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (80 to 160 mg once or twice daily)
Number of subjects: 48
Study 17322151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 15095555 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 0.9 mg/kg TPA with TCD monitoring
Number of subjects: 55
Study 11409475 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-strong graduated compression stocking
Number of subjects: 95
Study 11409475 — intervention group
Group type: COMPARATOR
Intervention: Standard graduated compression stocking
Number of subjects: 95
Study 9710023 — intervention group
Group type: EXPERIMENTAL
Intervention: 11C-flumazenil (FMZ) PET
Number of subjects: 24
Study 18173197 — intervention group
Group type: EXPERIMENTAL
Intervention: TFX‐thymomodulin
Number of subjects: 20
Study 18173197 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy only
Number of subjects: 20
Study 3202084 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive equations for total adipose-tissue volume based on weight/height
Number of subjects: 27
Study 3202084 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive equations for visceral adipose-tissue volume based on sagittal diameter of the trunk at the L3-L5 level
Number of subjects: 27
Study 30550176 — intervention group
Group type: EXPERIMENTAL
Intervention: Butylphthalide with non‐invasive ventilator
Number of subjects: 90
Study 30550176 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group of butylphthalide
Number of subjects: 90
Study 30550176 — intervention group
Group type: COMPARATOR
Intervention: Non‐invasive ventilator group
Number of subjects: 90
Study 25881731 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath MAC video laryngoscope
Number of subjects: 66
Study 25881731 — intervention group
Group type: COMPARATOR
Intervention: King Vision video laryngoscope
Number of subjects: 66
Study 26427036 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic tablet containing Streptococcus oralis KJ3, Streptococcus uberis KJ2 and Streptococcus rattus JH145, used twice a day for 12 weeks
Number of subjects: 48
Study 26427036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 26427036 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic tablet
Number of subjects: 48
Study 23688334 — intervention group
Group type: EXPERIMENTAL
Intervention: BF (breakfast diet)
Number of subjects: 60
Study 23688334 — intervention group
Group type: COMPARATOR
Intervention: D (dinner diet)
Number of subjects: 60
Study 20533245 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) supplementation (159 mg/day total catechins)
Number of subjects: 9
Study 20533245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 18835479 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) with integrated emotion-regulation training
Number of subjects: 289
Study 18835479 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral treatment (CBT)
Number of subjects: 289
Study 16633780 — intervention group
Group type: EXPERIMENTAL
Intervention: Target blood propofol concentration of 5 microg x ml(‐1) (group 1)
Number of subjects: 36
Study 16633780 — intervention group
Group type: COMPARATOR
Intervention: Target blood propofol concentration of 6 microg x ml(‐1) (group 2)
Number of subjects: 36
Study 16633780 — intervention group
Group type: EXPERIMENTAL
Intervention: Target blood concentration set at 1.67 times that of the desired C(e) for 1 min, after which it should revert to the desired concentration.
Number of subjects: 36
Study 12767102 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin plus placebo
Number of subjects: 630
Study 10768088 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 2 mg twice daily
Number of subjects: 303
Study 10768088 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg twice daily
Number of subjects: 303
Study 10768088 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 6 mg twice daily
Number of subjects: 303
Study 10768088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study 10768088 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (all doses)
Number of subjects: 303
Study 9313277 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of lorazepam in addition to standard opioid analgesics
Number of subjects: 79
Study 9313277 — intervention group
Group type: COMPARATOR
Intervention: Placebo in addition to standard opioid analgesics
Number of subjects: 79
Study 8101583 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular naloxone (0.04 mg)
Number of subjects: 22
Study 8101583 — intervention group
Group type: COMPARATOR
Intervention: Intravenous naloxone (0.04 mg)
Number of subjects: 22
Study 2943703 — intervention group
Group type: EXPERIMENTAL
Intervention: ORS plus boiled-rice feeding
Number of subjects: 48
Study 2943703 — intervention group
Group type: COMPARATOR
Intervention: ORS alone
Number of subjects: 48
Study 30341259 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up 24 and 72 hours after surgery
Number of subjects: 638
Study 30341259 — intervention group
Group type: COMPARATOR
Intervention: Control group (no telephone follow-up)
Number of subjects: 638
Study 30341259 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Number of subjects: 638
Study 27506593 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with severe dental anxiety (DAS score ≥ 13)
Number of subjects: 76
Study 27506593 — intervention group
Group type: COMPARATOR
Intervention: Control group from the general population
Number of subjects: 76
Study 24444428 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP and laser treatment (810 nm diode laser using the 'hot tip' technique at ∼ 760 °C)
Number of subjects: 21
Study 24444428 — intervention group
Group type: COMPARATOR
Intervention: SRP treatment alone
Number of subjects: 21
Study 22857018 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-s high-intensity training (HIT) involving 10 × 6-s sprints for 2 weeks
Number of subjects: 6
Study 22857018 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-s high-intensity training (HIT)
Number of subjects: 6
Study 22857018 — intervention group
Group type: COMPARATOR
Intervention: Normal training routine (control group, N=6, age 36 ± 9 years, weight 82 ± 11 kg, BMI 26 ± 3 kg·m⁻²)
Number of subjects: 6
Study 19895855 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma enhancing neurofeedback
Number of subjects: 0
Study 19895855 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 18240282 — intervention group
Group type: EXPERIMENTAL
Intervention: VSL#3 (2 sachets once daily for 12 months)
Number of subjects: 31
Study 18240282 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 31
Study 15731606 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal levobupivacaine
Number of subjects: 100
Study 15731606 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal ropivacaine
Number of subjects: 100
Study 15731606 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal levobupivacaine and ropivacaine at doses of 2.5 mg or greater
Number of subjects: 100
Study 15731606 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal levobupivacaine and ropivacaine
Number of subjects: 100
Study 12828793 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-rich diet supplying 10% energy as trans-18:1
Number of subjects: 29
Study 12828793 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleate diet
Number of subjects: 29
Study 12828793 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate diet
Number of subjects: 29
Study 12828793 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans diet
Number of subjects: 29
Study 10751234 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet
Number of subjects: 20
Study 10751234 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet plus dexfenfluramine (Df)
Number of subjects: 20
Study 10751234 — intervention group
Group type: COMPARATOR
Intervention: Combined data from both treatments
Number of subjects: 20
Study 8857882 — intervention group
Group type: EXPERIMENTAL
Intervention: Low to moderate intensity exercise program (stretching, postural control, endurance walking, coordination exercises)
Number of subjects: 65
Study 8857882 — intervention group
Group type: EXPERIMENTAL
Intervention: Low to moderate intensity exercise program with obstacle course practice
Number of subjects: 65
Study 8857882 — intervention group
Group type: EXPERIMENTAL
Intervention: Low to moderate intensity exercise program
Number of subjects: 65
Study 1346171 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCM (adriamycin, BCNU, cyclophosphamide, and melphalan)
Number of subjects: 630
Study 1346171 — intervention group
Group type: COMPARATOR
Intervention: Melphalan (M7)
Number of subjects: 630
Study 6201409 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon-arc photocoagulation treatment
Number of subjects: 107
Study 6201409 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated) eyes
Number of subjects: 107
Study 6201409 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated eyes with peripheral new vessels only
Number of subjects: 107
Study 30157224 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐diagnostic smoking
Number of subjects: 3304
Study 30157224 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐diagnostic obesity
Number of subjects: 3304
Study 27301849 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (nCRT) followed by esophagectomy
Number of subjects: 322
Study 27301849 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 322
Study 24240315 — intervention group
Group type: COMPARATOR
Intervention: Moderate neuromuscular block (train-of-four 1-2) using atracurium/mivacurium
Number of subjects: 24
Study 24240315 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block (post-tetanic count 1-2) using high-dose rocuronium
Number of subjects: 24
Study 22325684 — intervention group
Group type: EXPERIMENTAL
Intervention: PWB training with audio feedback
Number of subjects: 38
Study 22325684 — intervention group
Group type: COMPARATOR
Intervention: Control group (PWB training without audio feedback)
Number of subjects: 38
Study 20433313 — intervention group
Group type: EXPERIMENTAL
Intervention: 915 MHz microwave ablation
Number of subjects: 39
Study 20433313 — intervention group
Group type: COMPARATOR
Intervention: 2450 MHz microwave ablation
Number of subjects: 39
Study 18417088 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioguided surgery (RGS) with 5 mCi technetium-99m in group 1
Number of subjects: 33